Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. PMID: 39213982
- PMID: 39798435
- DOI: 10.1016/j.vaccine.2024.126701
Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. PMID: 39213982
Erratum for
-
How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. Vaccine. 2024. PMID: 39213982
Publication types
LinkOut - more resources
Full Text Sources